All News
Can we withdraw treatment in post-menopausal osteoporosis?
EurekAlert!
Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk.
Read Article
Dual seropositivity and shared epitopes in RA: friends or foes?
Dual seropositivity (rheumatoid factor and/or anti-citrullinated protein antibodies) as well as shared epitope are known to be associated with poor prognosis and structural damage in RA.
Read Article
#EULARBest @RheumNow https://t.co/cCv88iTCTV
Aurelie Najm AurelieRheumo ( View Tweet)
ARGO trial Ph 2 RCT Sonelokimab IL-17A/Fi Nanobody
Wk 12, primary ACR50
ACR 50 SON 120 mg 46% 60 mg 46% PBO 20%
PASI 90 SON 120 mg 60% 60 mg 77% PBO 15%
MDA SON 60mg 47% PBO 20%
No new safety signal
#EULAR2024 @RheumNow AbstrOP0195 https://t.co/4W5KFi23za
Aurelie Najm AurelieRheumo ( View Tweet)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PH 2/3 STUDY OF SHR0302, A SELECTIVE JAK 1 INHIBITOR, IN PATIENTS WITH ACTIVE AS - behaves like a JAK in AxSpA now as well as in RA - safety is clean/no new signals but where is the zoster? @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
Baseline predictors of D2TRA in naive recent onset RA 1000pts
-female sex
-higher joint count
-erosions
-pulmonary involvement
-depression
-fatigue
#EULAR24 AbstOP0118 @RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
COMPARATIVE SAFETY OF JAK INHIBITORS VERSUS TNF OR IL-17 INHIBITORS FOR CARDIOVASCULAR DISEASE, VENOUS THROMBOEMBOLISM AND CANCER IN PSORIATIC ARTHRITIS AND AXIAL - no signal of significant difference but channeling bias last few years @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
COMPARATIVE RISK OF MORTALITY IN NEW USERS OF PRESCRIPTION OPIOIDS FOR NON-CANCER PAIN: RESULTS FROM THE INTERNATIONAL PHARMACOSURVEILLANCE STUDY - HR 9-13 increased deaths narcotic use compared with codeine UK Boston Montreal >1 million pts included @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
3 pain clusters in AxSpA - tres intéressant @RheumNow #EULAR2024 https://t.co/ZgXvsxHlJu
Peter Nash drpnash ( View Tweet)
OP0202 looks at phenotypes of #RAILD in a cluster analysis
🌎Large multinational cohort
2⃣Two key clusters identified
📈Male sex, older age at RA & ILD onset, European ethnicity, smoking and CCP & RF positivity more frequent in cluster 1 vs 2
@RheumNow #EULAR2024 @Juge_P_A
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty
Dr. John Cush RheumNow ( View Tweet)
GOLMePsA RCT early naive PsA
Golimumab or PBO in addition to MTX+IM GCs
No difference wk52
ACR20 GOL 76% PBO 55%
MDA GOL 55% PBO 41%
PBO arm received higher GC dose
No new safety signal
@RheumNow AbstOP0148 #EULAR2024 https://t.co/bj7YNXhssm
Aurelie Najm AurelieRheumo ( View Tweet)
📺 Join @RheumNow, @Yuz6Yusof & I for the Daily Recap over on @YouTube
⏩ https://t.co/D3HZGUdi9t
⏰ TODAY 18:00 CEST
👋 See you there!
#EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
Nationwide epi study of lymphoproliferative disorders in Sjogren's. All pts in France!
4 % prevalence
More in males and those with cryos and MGUS
#EULAR2024
@rheumnow
abst#OP0207 https://t.co/bEaWpTD7x3
Links:
Bella Mehta bella_mehta ( View Tweet)
Severe refractory Sjogrens - not in RCTs but some meds such as CD20 - Obinutuzumab, CART have been reported.
A summary of slides @RheumNow https://t.co/9HQRAj3rzt
Links:
Bella Mehta bella_mehta ( View Tweet)
CD40 and CD40L (CD154) inhibition
CD-40 monoclonal antibody
CD 40 Ligand blockade- Dazodalibep
@RheumNow https://t.co/n9CcrujVwa
Links:
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 POS0237 RNA-seq of muscle biopsy in inflammatory myopathy (IIM) showed distinct gene expressions underlying muscle damage between DM, Antisynthetase & PM. Potential targets for future therapeutics @RheumNow @IzukaShinji https://t.co/nf0pp2RhaE
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Current and future treatment in Sjogrens Syndrome @rheumnow #EULAR2024
Many failed trails - likely secondary to non validated outcomes.
3 major domains - sicca, extraglandular manifestations, constitutional https://t.co/cCYX1YCqG2
Links:
Bella Mehta bella_mehta ( View Tweet)
"T and B cells playing tennis" In Sjogren's Syndrome!
Thomas Dorner - #EULAR2024 @rheumnow https://t.co/Lum0A9cY9U
Bella Mehta bella_mehta ( View Tweet)
Isolated ⬆️ serum #IgG4 level:
💎💎💎 (Dr. Stone):
❓How high? >5x ULN ➡️PPV 75%‼️
❓Typical organ(s) involved?
❓Another explanation?
#eular2024
#rheumx
@eular_org
@RheumNow https://t.co/pm6wjvi2Vt
Links:
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
